» Articles » PMID: 30894814

Therapeutic Potential of Targeting ß-Arrestin

Overview
Journal Front Pharmacol
Date 2019 Mar 22
PMID 30894814
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent signaling, initiation of ß-arrestin-dependent signaling, receptor trafficking to degradative or recycling pathways, receptor transactivation, transcriptional regulation, and localization of second messenger regulators. The pleiotropic influence ß-arrestins exert on these receptors regulates a breadth of physiological functions, and additionally, ß-arrestins are involved in the pathophysiology of numerous and wide-ranging diseases, making them prime therapeutic targets. In this review, we briefly describe the mechanisms by which ß-arrestins regulate GPCR signaling, including the functional cellular mechanisms modulated by ß-arrestins and relate this to observed pathophysiological responses associated with ß-arrestins. We focus on the role for ß-arrestins in transducing cell signaling; a pathway that is complementary to the classical G protein-coupling pathway. The existence of these GPCR dual signaling pathways offers an immense therapeutic opportunity through selective targeting of one signaling pathway over the other. Finally, we will consider several mechanisms by which the potential of dual signaling pathway regulation can be harnessed and the implications for improved disease treatments.

Citing Articles

Combining Single-Cell RNA Sequencing and Mendelian Randomization to Explore Novel Drug Targets for Parkinson's Disease.

Wu X, Wang K, Li Q, Zhang Y, Wei P, Shan Y Mol Neurobiol. 2025; .

PMID: 39890696 DOI: 10.1007/s12035-025-04700-3.


Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.

Fisher G, Travers J, Rohan C Front Med (Lausanne). 2024; 10:1292722.

PMID: 38193038 PMC: 10773789. DOI: 10.3389/fmed.2023.1292722.


β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review.

Gelape F, Couto C, Cancado G Am J Trop Med Hyg. 2023; 109(6):1213-1219.

PMID: 37931294 PMC: 10793037. DOI: 10.4269/ajtmh.23-0437.


Investigation of adenosine A1 receptor-mediated β-arrestin 2 recruitment using a split-luciferase assay.

Saecker L, Haberlein H, Franken S Front Pharmacol. 2023; 14:1172551.

PMID: 37324481 PMC: 10268005. DOI: 10.3389/fphar.2023.1172551.


Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?.

Sauerbruch T, Hennenberg M, Trebicka J, Schierwagen R Front Med (Lausanne). 2023; 9:1100966.

PMID: 36743678 PMC: 9891090. DOI: 10.3389/fmed.2022.1100966.


References
1.
Laporte S, Oakley R, Zhang J, Holt J, Ferguson S, Caron M . The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A. 1999; 96(7):3712-7. PMC: 22359. DOI: 10.1073/pnas.96.7.3712. View

2.
Bohn L, Lefkowitz R, Gainetdinov R, Peppel K, Caron M, Lin F . Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 2000; 286(5449):2495-8. DOI: 10.1126/science.286.5449.2495. View

3.
Smith W, Gurevich E, Dugger D, Vishnivetskiy S, Shelamer C, McDowell J . Cloning and functional characterization of salamander rod and cone arrestins. Invest Ophthalmol Vis Sci. 2000; 41(9):2445-55. View

4.
Shenoy S, McDonald P, Kohout T, Lefkowitz R . Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science. 2001; 294(5545):1307-13. DOI: 10.1126/science.1063866. View

5.
Covic L, Gresser A, Talavera J, Swift S, Kuliopulos A . Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A. 2002; 99(2):643-8. PMC: 117359. DOI: 10.1073/pnas.022460899. View